VYGR vs. ANIP, SPRY, AUPH, SNDX, SYRE, ELVN, COLL, BCYC, NTLA, and RCKT
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.
Voyager Therapeutics vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Voyager Therapeutics had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 10 mentions for Voyager Therapeutics and 9 mentions for ANI Pharmaceuticals. Voyager Therapeutics' average media sentiment score of 0.67 beat ANI Pharmaceuticals' score of 0.41 indicating that Voyager Therapeutics is being referred to more favorably in the news media.
ANI Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
ANI Pharmaceuticals received 41 more outperform votes than Voyager Therapeutics when rated by MarketBeat users. However, 67.64% of users gave Voyager Therapeutics an outperform vote while only 64.58% of users gave ANI Pharmaceuticals an outperform vote.
Voyager Therapeutics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ANI Pharmaceuticals currently has a consensus price target of $77.71, indicating a potential upside of 32.94%. Voyager Therapeutics has a consensus price target of $15.97, indicating a potential upside of 214.92%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than ANI Pharmaceuticals.
Voyager Therapeutics has a net margin of 15.80% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Voyager Therapeutics' return on equity.
Summary
Voyager Therapeutics beats ANI Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VYGR) was last updated on 1/20/2025 by MarketBeat.com Staff
